Boehringer Ingelheim Company Profile

What is the competitive landscape for BOEHRINGER INGELHEIM

BOEHRINGER INGELHEIM has fifty approved drugs.

There are seventy-four US patents protecting BOEHRINGER INGELHEIM drugs.

Summary for Boehringer Ingelheim

US Patents:	74
Tradenames:	39
Ingredients:	31
NDAs:	50
Patent Litigation for Boehringer Ingelheim:	See patent lawsuits for Boehringer Ingelheim
PTAB Cases with Boehringer Ingelheim as petitioner:	See PTAB cases with Boehringer Ingelheim as petitioner

Drugs and US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No	10,022,379		Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020		RX	Yes	No	8,551,957*PED				Y
Boehringer Ingelheim	SYNJARDY	empagliflozin; metformin hydrochloride	TABLET;ORAL	206111-002	Aug 26, 2015		RX	Yes	No	10,610,489*PED				Y
Boehringer Ingelheim	SYNJARDY	empagliflozin; metformin hydrochloride	TABLET;ORAL	206111-003	Aug 26, 2015		RX	Yes	No	7,713,938*PED				Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes	7,579,449*PED				Y

Expired US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-001	Nov 10, 1998	5,591,762
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	7,786,111
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-007	Jul 30, 2007	6,001,861
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-002	Jul 1, 1997	6,194,445
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	5,964,416

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	10 mg and 25 mg		2018-08-01
	Tablets	20 mg, 40 mg and 80 mg		2006-12-26
	Tablets	80 mg/25 mg		2009-02-27
	Capsules	100 mg and 150 mg		2018-10-15
	Tablets	0.25 mg		2005-05-27
	Capsules	eq. to 110 mg base		2015-12-15
	Oral Suspension	7.5 mg/5 mL		2009-12-17
	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg		2018-03-28
	Tablets	5 mg		2015-05-04
	Extended-release Tablets	2.25 mg and 3.75 mg		2011-07-26
	Extended-release Tablets	400 mg		2013-06-21
	Tablets	10 mg/5 mg and 25 mg/5 mg		2018-08-01
	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg		2015-05-04
	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg		2008-12-31
	Extended-release Capsules	25 mg and 200 mg		2007-02-01
	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg		2005-06-24
	Capsules	eq. to 75 mg base and 150 mg base		2014-10-20
	Tablets	0.75 mg		2008-07-31
	Inhalation Powder Capsules	18 mcg		2018-05-11
	Tablets	5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg		2018-08-01
	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg		2010-06-01
	Extended-release Tablets	5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg		2018-08-01
	Tablets	20 mg, 30 mg and 40 mg		2017-07-12

International Patents for Boehringer Ingelheim Drugs

Country	Patent Number	Estimated Expiration
Germany	102007045438
Argentina	041969
Norway	20070719
Singapore	182552
Eurasian Patent Organization	011158

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2525812	17C1026	France		PRODUCT NAME: IDARUCIZUMAB; REGISTRATION NO/DATE: EU/1/15/1056 20151124
1830843	254 5015-2015	Slovakia		PRODUCT NAME: NINTEDANIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/979/001 - EU/1/14/979/004 20150119
1971601	SPC/GB21/042	United Kingdom		PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU/1/20/1526(FOR NI) 20210212; UK FURTHER MAS ON IPSUM 20210212
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
2525812	CA 2017 00031	Denmark		PRODUCT NAME: IDARUCIZUMAB; REG. NO/DATE: EU/1/15/1056 20151124

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Boehringer Ingelheim